News

The British pharma giant also said that it is weighing options for its Rare Diseases business which it is looking to divest in the near future following a

The funding will be used to support discovery and preclinical development of a new class of antibiotic that circumvents β-lactam antibiotic resistance, but with the same safe and

Proceeds will be used to advance the company’s portfolio, including lead product candidate VNRX-5133 for multi-drug resistant (MDR) gram-negative infections. In connection with the financing, Versant Partner Carlo

The litigation related primarily to allegations that Celgene promoted Thalomid (thalidomide) for off-label uses before its 2006 FDA approval for newly diagnosed multiple myeloma. The Department of Justice,

The trial dubbed KEYNOTE-040 was held in patients who had previously undergone treatment for HNSCC and whose disease had recurred or is in a metastatic stage. While the

"This is a great result for the Mitchell family and all the other victims of AbbVie's fraudulent conduct. Today, this jury sent a clear message. AbbVie, hopefully, hears

NKTR-358, which achieved first human dose in Phase 1 clinical development in March of 2017, has the potential to treat a number of autoimmune and other chronic inflammatory

The deal will help MTPC grow its product pipeline in the central nervous system disease area. The company intends to offer patients with innovative drugs for unmet medical needs.  

The grant from CIRM is a significant endorsement of the potential for Brainstorm's novel approach to treat ALS using adult stem cells. CIRM is the World's Largest Institution